With two ADCs showing strong frontline data, is there still a place for chemotherapy?
Dr. Hamilton explains why many patients may benefit more from ADCs first — especially rapid relapsers — and why “best drugs first” matters in mTNBC where not all patients reach multiple subsequent lines of therapy.
